Kathryn E Webert

, MD, MSc, FRCPC

Associate Professor, Pathology and Molecular Medicine

Division: Clinical Pathology

Medical Director of Utilization Management
Medical, Scientific and Research Affairs Division
Candian Blood Services

McMaster University
HSC-2N29 Health Sciences Centre
Hamilton, Ontario

905-521-2100 Ext. 76274
Fax: 905-521-2338
webertk@mcmaster.ca

Assistant: Cindy Bailey

Education and Professional Standing

BSc, Queen's University, 1992

MD, University of Western Ontario, 1996

FRCPC Internal Medicine, 2000

FRCPC Hematology 2001

MSc (HRM), McMaster University, 2009

FRCPC Clinical Investigator, 2009

Graduate Diploma in Health Services and Policy Research, Ontario Training Council and McMaster University, 2009

---

Interests

Research Focus

Dr. Webert's areas of research interest include bleeding in patients with bone marrow failure and the utilization of blood products. She was the co-principal investigator of a pilot clinical trial to investigate the role of hemoglobin level on the frequency of bleeding in patients with acute leukemia and patients undergoing stem cell transplantation. She has also developed a measurement tool to accurately document the severity of bleeding episodes. She is a recipient of several operating grants from Canadian Blood Services and a McMaster Department of Medicine Internal Career Award.

Clinical Focus

Dr. Webert's clinical interests include transfusion medicine, benign hematology, and hemostasis and coagulation. 

Academic Interests

Dr. Kathryn Webert is an Associate Professor with the Department of Medicine and the Department of Molecular Medicine and Pathology, an investigator with the McMaster Transfusion Research Program, and an Associate Medical Director with Canadian Blood Services.  She is the Director of Operations for Transfusion Services within the HRLMP.  Dr. Webert is involved in teaching medical residents within the Hematology, Internal Medicine, Pathology and Transfusion Medicine residency programs.

---

Selected Publications

Webert KE, Rivard GE, Teitel J, Carcao M, Lillicrap D, Saint-Louis J, Walker I.  Low prevalence of inhibitor antibodies in the Canadian haemophilia population.  Haemophilia. 2011 Nov 14. doi: 10.1111/j.1365-2516.2011.02694.x. [Epub ahead of print].

Eyles J, Heddle N, Webert K, Arnold E, McCurdy B.  Do expert assessments converge?  An exploratory case study of evaluating and managing a blood supply risk.  BMC Public Health 2011; 11:666.

Pai M, Wang G, Moffat K, Liu Y, Seecharan J, Webert K, Heddle N, Hayward C. Diagnostic Utility of a Lumiaggregometer Adenosine Triphosphate Release Assay for the Assessment of Platelet Function Disorders. American Journal of Clinical Pathology 2011; 136(3):350-358.

Heddle NM, Arnold DM, Webert KE. Time to rethink clinically important outcomes in platelet transfusion trials. Transfusion 2011;51:430-434.

Heddle NM, Lui Y, Barty R, Webert KE, Whittaker S, Gagliardi KF, Lauzon D, Owens W.  Factors affecting the frequency of red cell outdates:  an approach to establishing benchmarking targets.  Transfusion 2009; 49:219-226.

Foley SR, Webert K, Arnold DM, Rock GA, Clark WF, Barth D, Sutton DM and Members of the Canadian Apheresis Group (CAG).  A Canadian Phase II Study Evaluating the Efficacy of Rituximab in the Management of Patients with Relapsed /Refractory Thrombotic Thrombocytopenic Purpura (TTP). Kidney International Suppl 2009; 112:S55-58.

Hayward CP, Pai M, Liu Y, Moffat KA, Seecharan J, Webert KE, Cook RJ, Heddle NM. Diagnostic utility of light transmission platelet aggregometry: results from a prospective study of individuals referred for bleeding disorder assessments. J Thromb Haemost 2009; 7:676-684.

Heddle NM, Eyles J, Webert KE, Arnold E, McCurdy BR. A policy informing qualitative study to improve the process of blood product recalls and withdrawals. Transfusion 2008; 48:2585-2595.

Carcao MD, Webert KE. On-label versus off-label use of recombinant activated factor VII: a comprehensive review of use in two Canadian centers. Semin Hematol. 2008;45(2 Suppl 1):S68-71.

Heddle NM, Arnold DM, Boye D, Webert KE, Resz I, Dumont LJ. Comparing the efficacy and safety of apheresis and whole blood-derived platelet transfusions: a systematic review. Transfusion 2008; 48:1447-1458.

Webert KE, Cook RJ, Couban S, Carruthers J, Lee KA, Blajchman MA, Lipton JH, Brandwein JM, Heddle NM. A multicenter pilot randomized controlled trial of the feasibility of an augmented red blood cell transfusion strategy for patients treated with induction chemotherapy for acute leukemia or stem cell transplantation. Transfusion 2008; 48(1): 81-91.

Webert KE, Arnold DM, Molnar, L, Carruthers J, Almonte T, Decker K, Seroski W, Reed J, Chan A, Pai M, Walker I. Utilization of recombinant activated factor VII in Southern Ontario in 85 patients with and without hemophilia. Haemophilia 2007; 13:518-26.

Webert KE, Cook RJ, Sigouin CS, Rebulla P, Heddle NM. The risk of bleeding in thrombocytopenic patients with acute myeloid leukemia. Haematologica 2006; 91:1530-1537.

Webert KE, Cook RJ, Couban S, Carruthers, J, Heddle N. A study of the agreement between patient self-assessment and study personnel assessment of bleeding symptoms. Transfusion 2006; 46:1926-1933.

Cook RJ, Heddle NM, Rebulla P, Sigouin C, Webert KE. Methods for the Analysis of Bleeding Outcomes in Randomized Trials of Platelet Transfusion Triggers. Transfusion 2004; 44:1135-42.

Webert KE, Mittal R, Sigouin C, Heddle NM, Kelton JG. A retrospective, 11-year analysis of obstetrical patients with Idiopathic Thrombocytopenic Purpura. Blood 2003; 102:4306-11.

Heddle NM, Cook RJ, Webert KE, Sigouin C, Rebulla P. Methodological issues in the use of bleeding as an outcome in transfusion medicine studies. Transfusion 2003; 43:742-52.